CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And Investors
CEL-SCI announced successful Phase III clinical trial results of its drug Multikine, which could mean fresh upside for the…
CEL-SCI announced successful Phase III clinical trial results of its drug Multikine, which could mean fresh upside for the…
Both CCIV and NIO have exhibited strong capabilities in matching customer demand with suitable EV models and technology. Find…
I remain massively convinced of TeamViewer’s fundamental business strategy and the capabilities of management.
As we reach halftime of calendar year, investors go into locker room with some knowledge of pandemic recovery and…
Coeur Mining is one of the worst-performing silver miners this year, down more than 20% year-to-date.
Walgreens Boots Alliance’s stock has little downside risk due to its valuation, while the upside potential is great as…
Imago BioSciences has filed to raise $105 million in an IPO and $20 million in a concurrent private placement….
CorePoint Lodging (CPLG) continued to execute on its non-core disposition strategy with 25 non-core hotels sold in the Q2, for…
Natural gas was unable to break above the critical resistance around $3.77/MMBtu. We have initiated a short position in…
Erasca has filed proposed terms for a $263 million IPO. The firm is developing treatment candidates for solid and…